Connor, Clark & Lunn Investment Management Ltd.
Position in ELVN — Enliven Therapeutics, Inc.
CIK 1596800
VANCOUVER, A1
Position in ELVN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$8,164,608
+$665,923 QoQ
Shares Held
160,879
-15.9% QoQ
Ownership
0.220%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#64
of 210 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ELVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Connor, Clark & Lunn Investment Management Ltd. holds $650,455,382 across 105 Biotechnology names. ELVN ranks #21 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
135,236 | $67,175,777 | |
| 2 | IONS |
Ionis Pharmaceuticals Inc
|
684,236 | $54,253,072 | |
| 3 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
625,569 | $50,990,129 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
420,063 | $49,176,775 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
42,465 | $26,478,625 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
97,698 | $23,913,539 | |
| 7 | INSM |
INSMED Inc
|
212,676 | $22,675,515 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
530,607 | $20,698,979 |
All Filings in ELVN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,164,608 | 160,879 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $7,498,685 | 191,293 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $2,998,919 | 194,735 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $711,926 | 34,779 | Shares | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||